SOURCE: SciClone Pharmaceuticals, Inc.

SciClone Pharmaceuticals, Inc.

November 01, 2011 07:00 ET

SciClone Pharmaceuticals to Report Third Quarter 2011 Financial Results on November 8

FOSTER CITY, CA--(Marketwire - Nov 1, 2011) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report third quarter 2011 financial results on Tuesday, November 8, 2011. SciClone will host a conference call to give a business and product update at 8:30 am ET that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Gary Titus, Senior Vice President and CFO.

LIVE CALL:
877-556-5921 (U.S./Canada)
617-597-5474 (International)
Passcode: 45149576

REPLAY:
888-286-8010 (U.S./Canada)
617-801-6888 (International)
Passcode: 50188621
(Replay available from Tuesday, November 8, 2011, at 11:30 am ET until 11:59 pm ET on Tuesday, November 15, 2011)

The conference call will contain forward-looking statements. Interested parties who wish to listen to the webcast should visit the Investor Relations section of SciClone's website at www.sciclone.com. The information provided on the teleconference is accurate only at the time of the conference call, and SciClone will take no responsibility for providing updated information except as required by law.

About SciClone
SciClone Pharmaceuticals is a revenue-generating, profitable, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone's ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers according to the local regulatory approvals. Besides ZADAXIN, SciClone markets nearly 20 mostly partnered products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched interventional cardiology product. SciClone is also developing SCV-07 in a phase 2b trial for the delay to onset of oral mucositis in patients with head and neck cancer. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California. For additional information, please visit www.sciclone.com.

Ambien, Depakine, Stilnox, and Tritace are registered trademarks of Sanofi-Aventis.

Aggrastat is a registered trademark of Merck & Co., Inc.

Contact Information